PFE Stock Price Today (May 2026) — Pfizer Inc. Analysis & Key Metrics 2026-05-22
Pfizer Inc. (PFE) is trading at $25.90, down 0.19% today (as of May 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $29.00 (12.0% upside).
- Volatility remains elevated (10.71% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-1.20% YoY) alongside significant competitive pressures.
PFE Stock Analysis: Key Metrics & Valuation (May 2026)
Concise, actionable data for investors
Pfizer Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $204.07B
P/E Ratio
Forward P/E: 9.36
Revenue Growth
Year over Year
Analyst Target
+12.0% upside potential
Key Investor Questions About PFE
What investors need to know before buying
Based on current market data, PFE presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 50.01)
- Fundamentals say: Challenging (declining revenue trends)
PFE's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PFE investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $67.65B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, PFE stock traded between $21.97 and $28.75—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 10.71% annualized volatility and β=0.39, the stock exhibits low sensitivity to market moves—making PFE suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Pfizer Oncology Partnerships Add Detail To Valuation And Earnings Concerns
Pfizer (NYSE:PFE) has entered a new alliance with Sarah Cannon Research Institute to accelerate oncology clinical trials and broaden patient access. The company has also granted Rigel Pharmaceuticals exclusive rights to commercialize VEPPANU, an FDA approved PROTAC based breast cancer therapy. These agreements reflect fresh moves in Pfizer's oncology R&D and commercialization approach that have not been covered in earlier updates. Pfizer's stock closed at $25.9, with the share price up 2.3%...
2 Reasons to Watch PFE and 1 to Stay Cautious
Pfizer currently trades at $25.89 per share and has shown little upside over the past six months, posting a middling return of 2.7%. The stock also fell short of the S&P 500’s 10.8% gain during that period.
SPHD Pays Monthly Income Without Fail Since 2012; Here’s What Could Break the Streak
The Invesco S&P 500 High Dividend Low Volatility ETF (NYSEARCA:SPHD) sends income to shareholders every month, with distributions rising roughly 23% in 2025 and 2026 monthly payouts climbing to around $0.208 per share, with a current 30-day SEC yield of 4.5%. The question is whether that income rests on a durable foundation or whether recent ... SPHD Pays Monthly Income Without Fail Since 2012; Here’s What Could Break the Streak
Fed Hawks Now Rule. Will Warsh Go Along with Them?
As Kevin Warsh steps up to lead the Federal Reserve, the case for interest-rate cuts is disappearing. Plus, investment newsletter commentary on AI”s circular ecosystem, emerging markets, and SpaceX.
The Most Important Healthcare Stock You're Not Watching
Down more than 50% from its 2021 highs, this pharmaceutical giant has been forgotten by Wall Street.
Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.
The company’s partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.
Merck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer
Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.
Scott Melker explains why the Fed was secretly designed for banks
Scott Melker discusses the history and structure of the Federal Reserve and presents bitcoin as a decentralized alternative. “The Daily Wolf with Scott Melker” airs on Yahoo Finance every day at 12:00 p.m. Tune in for your daily dose of all things crypto.Make sure to also check out Yahoo Finance's new crypto hub to find the latest crypto-related news.
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Frequently Asked Questions
Common investor questions about Pfizer Inc.
Pfizer Inc. (PFE) is currently trading at $25.90. The RSI (14-day) is at 50.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $29.00 implies 12.0% upside from current levels. Volatility is low at 10.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Pfizer Inc. (PFE): The trailing P/E ratio is 19.36, which is in line with broader market averages. The forward P/E is 9.36, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 13.77, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 1.73. Price-to-Sales is 2.39. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 27 analysts covering PFE, the consensus price target is $29.00. This represents a 12.0% upside from the current price of $25.90. The range spans from a low target of $24.00 to a high target of $36.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Pfizer Inc. (PFE) pays a dividend with a current yield of approximately 6.64%. The annualized dividend rate is $1.72 per share. The payout ratio is 131.3%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-05-08.
Key risks for Pfizer Inc. (PFE) investors include: 1. Declining revenue (-1.2% YoY), indicating potential business headwinds. 2. Unsustainable dividend payout ratio (131%) could lead to a dividend cut. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Pfizer Inc.'s (PFE) current debt and financial health profile: Total debt stands at $67.65B. The debt-to-equity ratio is 77.96, which is moderate and generally manageable for most companies. The current ratio is 1.16, indicating adequate short-term liquidity. The quick ratio is 0.80. The company holds $13.60B in cash and equivalents. Free cash flow is positive at $13.43B, providing a cushion for debt servicing and shareholder returns.